Psoriasis and Atopic Dermatitis

[1]  Elizabeth A. Grice,et al.  The skin microbiome , 2020, Nature.

[2]  F. Gómez-García,et al.  Short‐term efficacy and safety of new biological agents targeting the interleukin‐23–T helper 17 pathway for moderate‐to‐severe plaque psoriasis: a systematic review and network meta‐analysis , 2017, The British journal of dermatology.

[3]  M. Reilly,et al.  Comparison of Coronary Artery Calcium Scores Between Patients With Psoriasis and Type 2 Diabetes. , 2016, JAMA dermatology.

[4]  A. Qureshi,et al.  Research Gaps in Quality of Life and Economic Burden of Atopic Dermatitis: The National Eczema Association Burden of Disease Audit. , 2016, JAMA dermatology.

[5]  P. Ong,et al.  Bacterial and Viral Infections in Atopic Dermatitis: a Comprehensive Review , 2016, Clinical Reviews in Allergy & Immunology.

[6]  B. Ferreira,et al.  Psoriasis and Associated Psychiatric Disorders: A Systematic Review on Etiopathogenesis and Clinical Correlation. , 2016, The Journal of clinical and aesthetic dermatology.

[7]  M. Arumugam,et al.  Comorbidities of Psoriasis - Exploring the Links by Network Approach , 2016, PloS one.

[8]  D. Leung,et al.  Recent considerations in the use of recombinant interferon gamma for biological therapy of atopic dermatitis , 2016, Expert opinion on biological therapy.

[9]  M. Lebwohl,et al.  US Perspectives in the Management of Psoriasis and Psoriatic Arthritis: Patient and Physician Results from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey , 2015, American Journal of Clinical Dermatology.

[10]  M. Lester.  Randomized Trial of Vitamin D Supplementation for Winter-Related Atopic Dermatitis in Children , 2015, Pediatrics.

[11]  A. Nast,et al.  Efficacy and Safety of Systemic Long-Term Treatments for Moderate-to-Severe Psoriasis: A Systematic Review and Meta-Analysis. , 2015, The Journal of investigative dermatology.

[12]  S. Beygi,et al.  Patients with psoriasis are at a higher risk of developing nonalcoholic fatty liver disease , 2015, Clinical and experimental dermatology.

[13]  H. Schünemann,et al.  Probiotics for the prevention of allergy: A systematic review and meta-analysis of randomized controlled trials. , 2015, The Journal of allergy and clinical immunology.

[14]  Tobias Kollmann,et al.  Early infancy microbial and metabolic alterations affect risk of childhood asthma , 2015, Science Translational Medicine.

[15]  A. Ogdie,et al.  Clinical Risk Factors for the Development of Psoriatic Arthritis Among Patients with Psoriasis: A Review of Available Evidence , 2015, Current Rheumatology Reports.

[16]  T. Mustelin,et al.  Past, present, and future for biologic intervention in atopic dermatitis , 2015, Allergy.

[17]  D. Nahm.  Personalized Immunomodulatory Therapy for Atopic Dermatitis: An Allergist's View , 2015, Annals of dermatology.

[18]  F. Spertini,et al.  EAACI IG Biologicals task force paper on the use of biologic agents in allergic disorders , 2015, Allergy.

[19]  P. Chatchatee,et al.  The natural course of childhood atopic dermatitis: a retrospective cohort study. , 2015, Asian Pacific journal of allergy and immunology.

[20]  M. Lebwohl,et al.  Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population‐based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey , 2015, Journal of the European Academy of Dermatology and Venereology : JEADV.

[21]  S. Nutten.  Atopic Dermatitis: Global Epidemiology and Risk Factors , 2015, Annals of Nutrition and Metabolism.

[22]  C. Lifschitz.  The Impact of Atopic Dermatitis on Quality of Life , 2015, Annals of Nutrition and Metabolism.

[23]  Xuejun Zhang,et al.  The immunological and genetic aspects in psoriasis , 2014, Applied Informatics.

[24]  G. Yancopoulos,et al.  Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[25]  B. Rao,et al.  Diet in dermatology: Part I. Atopic dermatitis, acne, and nonmelanoma skin cancer. , 2014, Journal of the American Academy of Dermatology.

[26]  D. Leung,et al.  Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. , 2014, The Journal of allergy and clinical immunology.

[27]  U. Mrowietz,et al.  Psoriasis: to treat or to manage? , 2014, Experimental dermatology.

[28]  H. Williams,et al.  Emollient enhancement of the skin barrier from birth offers effective atopic dermatitis prevention , 2014, The Journal of allergy and clinical immunology.

[29]  Takashi Sasaki,et al.  Application of moisturizer to neonates prevents development of atopic dermatitis. , 2014, The Journal of allergy and clinical immunology.

[30]  C. Camargo,et al.  Randomized trial of vitamin D supplementation for winter-related atopic dermatitis in children. , 2014, The Journal of allergy and clinical immunology.

[31]  C. Vestergaard,et al.  Clinical heterogeneity and differential diagnosis of atopic dermatitis , 2014, The British journal of dermatology.

[32]  Mayte Suárez-Fariñas,et al.  Immunology of psoriasis. , 2014, Annual review of immunology.

[33]  W. Liao,et al.  Genetic Epidemiology of Psoriasis , 2014, Current Dermatology Reports.

[34]  E. Louis,et al.  Cancer risk in immune-mediated inflammatory diseases (IMID) , 2013, Molecular Cancer.

[35]  M. Suárez-Fariñas,et al.  Intrinsic atopic dermatitis shows similar TH2 and higher TH17 immune activation compared with extrinsic atopic dermatitis. , 2013, The Journal of allergy and clinical immunology.

[36]  Rosa Parisi,et al.  Global epidemiology of psoriasis: a systematic review of incidence and prevalence. , 2013, The Journal of investigative dermatology.

[37]  C. Chew‐Graham,et al.  Recognition of need in health care consultations: a qualitative study of people with psoriasis , 2013, The British journal of dermatology.

[38]  L. Cordingley,et al.  Adherence to medication in patients with psoriasis: a systematic review , 2012 .

[39]  C. Chew‐Graham,et al.  Beyond skin: the need for a new approach to the management of psoriasis in primary care. , 2012, The British journal of general practice : the journal of the Royal College of General Practitioners.

[40]  Yinduo Ji,et al.  Staphylococcus aureus α-toxin modulates skin host response to viral infection. , 2012, The Journal of allergy and clinical immunology.

[41]  J. Ring,et al.  Guidelines for treatment of atopic eczema (atopic dermatitis) Part I , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[42]  E. Simpson.  Comorbidity in Atopic Dermatitis , 2012, Current Dermatology Reports.

[43]  K. Reich.  The concept of psoriasis as a systemic inflammation: implications for disease management , 2012, Journal of the European Academy of Dermatology and Venereology : JEADV.

[44]  J. Moreno,et al.  Treatment of severe refractory adult atopic dermatitis with ustekinumab , 2012, International journal of dermatology.

[45]  P. Rahman,et al.  Genetics of susceptibility and treatment response in psoriatic arthritis , 2011, Nature Reviews Rheumatology.

[46]  G. Murphy,et al.  In touch with psoriasis: topical treatments and current guidelines , 2011, Journal of the European Academy of Dermatology and Venereology : JEADV.

[47]  R. Clark.  Gone but not forgotten: lesional memory in psoriatic skin. , 2011, The Journal of investigative dermatology.

[48]  K. Szegedi,et al.  IL-17 and IL-22 in atopic allergic disease. , 2010, Current opinion in immunology.

[49]  A. Bowcock,et al.  Psoriasis genetics: breaking the barrier. , 2010, Trends in genetics : TIG.

[50]  F. Bernard,et al.  Skin Inflammation Induced by the Synergistic Action of IL-17A, IL-22, Oncostatin M, IL-1α, and TNF-α Recapitulates Some Features of Psoriasis , 2010, The Journal of Immunology.

[51]  J. Krueger,et al.  New insights in the immunologic basis of psoriasis. , 2010, Seminars in cutaneous medicine and surgery.

[52]  P. Gisondi,et al.  Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. , 2009, Journal of hepatology.

[53]  W. Gulliver,et al.  Psoriasis Comorbidities , 2009, Journal of cutaneous medicine and surgery.

[54]  A. Finlay,et al.  The Dermatology Life Quality Index 1994–2007: a comprehensive review of validation data and clinical results , 2008, The British journal of dermatology.

[55]  A. Kimball,et al.  Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1) , 2008, The Lancet.

[56]  M. Bala,et al.  Psoriasis: cardiovascular risk factors and other disease comorbidities. , 2008, Journal of drugs in dermatology : JDD.

[57]  Elizabeth J Horn,et al.  Are patients with psoriasis undertreated? Results of National Psoriasis Foundation survey. , 2007, Journal of the American Academy of Dermatology.

[58]  N. Prescott,et al.  Psoriasis is associated with pleiotropic susceptibility loci identified in type II diabetes and Crohn disease , 2007, Journal of Medical Genetics.

[59]  L. Fry,et al.  Triggering psoriasis: the role of infections and medications. , 2007, Clinics in dermatology.

[60]  R. Shikiar,et al.  The validity and responsiveness of three quality of life measures in the assessment of psoriasis patients: results of a phase II study , 2006, Health and quality of life outcomes.

[61]  Rajesh Balkrishnan,et al.  The Burden of Atopic Dermatitis: Impact on the Patient, Family, and Society , 2005, Pediatric dermatology.

[62]  C. Griffiths,et al.  Randomized comparison of the type 4 phosphodiesterase inhibitor cipamfylline cream, cream vehicle and hydrocortisone 17‐butyrate cream for the treatment of atopic dermatitis , 2002, The British journal of dermatology.

[63]  A. Finlay,et al.  Dermatology Life Quality Index (DLQI)—a simple practical measure for routine clinical use , 1994, Clinical and experimental dermatology.

[64]  C. Sherbourne,et al.  The MOS 36-Item Short-Form Health Survey (SF-36) , 1992 .

[65]  J. Machado-Pinto,et al.  Psoriasis: new comorbidities* , 2016, Anais brasileiros de dermatologia.

[66]  B. Sigurgeirsson,et al.  Throat Infections are Associated with Exacerbation in a Substantial Proportion of Patients with Chronic Plaque Psoriasis. , 2016, Acta dermato-venereologica.

[67]  G. Duarte,et al.  Psoriasis: classical and emerging comorbidities* , 2015, Anais brasileiros de dermatologia.

[68]  S. Feldman,et al.  A review of phosphodiesterase-inhibition and the potential role for phosphodiesterase 4-inhibitors in clinical dermatology. , 2014, Dermatology online journal.

[69]  J. Frew.  The clinical significance of drug interactions between dermatological and psychoactive medications , 2014, Dermatologic therapy.

[70]  E. Simpson,et al.  Eczema prevalence in the United States: data from the 2003 National Survey of Children's Health. , 2011, The Journal of investigative dermatology.

[71]  S. Feldman,et al.  The self-administered psoriasis area and severity index is valid and reliable. , 1996, The Journal of investigative dermatology.

[72]  A. Taïeb,et al.  Severity scoring of atopic dermatitis: the SCORAD index. Consensus Report of the European Task Force on Atopic Dermatitis. , 1993, Dermatology.

[73]  Julia Brasch,et al.  Severity Scoring of Atopic Dermatitis: The SCORAD Index , 1993 .

[74]  A. Kasuya.  EuroQol--a new facility for the measurement of health-related quality of life. , 1990, Health policy.

[75]  A. Williams.  EuroQol : a new facility for the measurement of health-related quality of life , 1990 .

[76]  I I Lelis,et al.  [Atopic dermatitis]. , 1980, Vestnik dermatologii i venerologii.